Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

First published online November 30, 2006
Stem Cells Vol. 25 No. 3 March 2007, pp. 707 -711
doi:10.1634/stemcells.2006-0469; www.StemCells.com
© 2007 AlphaMed Press

OPEN ACCESS ARTICLE
This Article
Free via Open Access: OA
Right arrow OA Full Text
Right arrow Full Text (PDF)
Right arrowOA All Versions of this Article:
2006-0469v1
25/3/707    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Costa, F. F.
Right arrow Articles by Brodin, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Costa, F. F.
Right arrow Articles by Brodin, B.

TRANSLATIONAL AND CLINICAL RESEARCH

Concise Review: Cancer/Testis Antigens, Stem Cells, and Cancer

Fabrício F. Costaa, Katarina Le Blancb, Bertha Brodinc

aCancer Biology and Epigenomics Program, Children's Memorial Research Center and Northwestern University's Feinberg School of Medicine, Chicago, Illinois, USA;
bCenter for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska University Hospital Huddinge, Stockholm, Sweden;
cCellular and Molecular Tumor Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden

Key Words. Cancer/testis antigens • Mesenchymal stem cells • Cancer stem cells • Cancer and therapeutics

Correspondence: Fabrício F. Costa, Ph.D., Children's Memorial Research Center–Cancer Biology and Epigenomics, 2300 Children's Plaza Box 220, Chicago, Illinois 60614-3394, USA. Telephone: 773-880-4000 ext 57402; Fax: 773-755-6551; e-mail: fcosta{at}childrensmemorial.org

Received July 26, 2006; accepted for publication November 17, 2006.
First published online in STEM CELLS EXPRESS   November 30, 2006.



In the multistep process of cancer development, the concept that cancer stem cells are derived from normal stem cells that have gradually accumulated various genetic and epigenetic defects is gaining strong evidence. A number of investigations have identified molecular markers that, under normal conditions, are responsible for stem cell homeostasis but are also expressed in tumor "stem cell-like" subpopulations. In this regard, it was recently reported that a group of tumor-specific antigens known as cancer/testis antigens (CTAs) are expressed in human MSCs. It has long been stated that in normal tissue these antigens are exclusively expressed in germ cell precursors; however, based on these results, we suggest that CTAs are expressed at earlier stages during embryogenesis. The tumor-restricted expression of CTAs has led to several immunotherapeutic trials targeting some of these proteins. The clinical implications that these trials may have on the normal stem cell pools, as well as the immunologic properties of these cells, is to date poorly studied and should be considered.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
O. Hofmann, O. L. Caballero, B. J. Stevenson, Y.-T. Chen, T. Cohen, R. Chua, C. A. Maher, S. Panji, U. Schaefer, A. Kruger, et al.
Genome-wide analysis of cancer/testis gene expression
PNAS, December 23, 2008; 105(51): 20422 - 20427.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2007 by AlphaMed Press.